Tesi etd-10152023-193028
Link copiato negli appunti
Tipo di tesi
Corso Ordinario Ciclo Unico 6 Anni
Autore
PANICHELLA, GIORGIA
URN
etd-10152023-193028
Titolo
Non-invasive assessment of left ventricular hemodynamics in hypertrophic cardiomyopathy: pathophysiological insights and impact of myosin inhibitor treatment
Struttura
Cl. Sc. Sperimentali - Medicina
Corso di studi
SCIENZE MEDICHE - SCIENZE MEDICHE
Commissione
relatore Prof. RECCHIA, FABIO ANASTASIO
Relatore Prof. EMDIN, MICHELE
Relatore Prof. EMDIN, MICHELE
Parole chiave
- Nessuna parola chiave trovata
Data inizio appello
18/12/2023;
Disponibilità
parziale
Riassunto analitico
Hemodynamic Force (HDF) analysis allows the study of blood motion within ventricular chambers through the exploration of the intraventricular pressure gradients. The HDF analysis is able to amplify mechanical abnormalities, detecting them earlier compared with conventional ejection fraction and cardiac strain analysis. Until recently, the HDF investigation has only been possible through contrast-echocardiography and magnetic resonance.
In this study, we employed a simplified mathematical model based on the first principle of fluid dynamics to estimate HDF at two-dimensional transthoracic echocardiographic in 80 patients with hypertrophic cardiomyopathy (HCM). Among these 80 patients, 40 had obstructive HCM and 40 non obstructive HCM. Each group further contained 20 patients with a positive genetic test (either pathogenic or likely pathogenic) and 20 with a negative genetic test (including variants of uncertain significance [VUS]). Furthermore, HDF were estimated in 6 patients with obstructive HCM at baseline and after treatment with the first-in-class myosin inhibitor, mavacamten.
In this study, we employed a simplified mathematical model based on the first principle of fluid dynamics to estimate HDF at two-dimensional transthoracic echocardiographic in 80 patients with hypertrophic cardiomyopathy (HCM). Among these 80 patients, 40 had obstructive HCM and 40 non obstructive HCM. Each group further contained 20 patients with a positive genetic test (either pathogenic or likely pathogenic) and 20 with a negative genetic test (including variants of uncertain significance [VUS]). Furthermore, HDF were estimated in 6 patients with obstructive HCM at baseline and after treatment with the first-in-class myosin inhibitor, mavacamten.
File
| Nome file | Dimensione |
|---|---|
Ci sono 1 file riservati su richiesta dell'autore. |
|